Mount Sinai Health System

Mount Sinai Is First in New York to Test Revolutionary Brain-Computer Implant Designed to Map Brain Activity in Unprecedented Detail

Retrieved on: 
Friday, March 22, 2024
Principal, Electric potential, Speech, Culture, Brain, BCI, Health, Assistant, Associate, Patient, DSM-IV codes, Research, Electrophysiology, Doctor of Philosophy, Translation, MD, Quality of life, Science, Behavior, Mount Sinai Health System, Medical imaging

A brain-computer interface (BCI) is a system that deciphers brain signals and translates them into commands for external technologies.

Key Points: 
  • A brain-computer interface (BCI) is a system that deciphers brain signals and translates them into commands for external technologies.
  • The film is one-fifth the thickness of a human hair and was designed to be implanted and removed by neurosurgeons without damaging brain tissue.
  • Dr. Rapoport also serves as the Scientific Director of Mount Sinai BioDesign, a medical technology prototyping center and incubator housed within the Mount Sinai Health System.
  • All Precision Neuroscience research at Mount Sinai is conducted by independent investigators without financial ties to the company.

Precision Neuroscience Expands Clinical Research In Brain–Computer Interface

Retrieved on: 
Friday, March 22, 2024
Brain, BCI, Motor cortex, Assistant, Associate, Partnership, University, Patient, Deep brain stimulation, DSM-IV codes, Research, Sale, Electrode, Parkinson's disease, Trial of the century, Behavior, Hospital, Optimism, Precision, DBS, Mount Sinai Health System, Movement, Hand, Health, Medical device

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).
  • Its design allows for safe implantation and removal by neurosurgeons without causing harm to delicate brain tissue.
  • Dr. Ben Rapoport, Chief Science Officer and co-founder of Precision Neuroscience, underscored the significance of these studies in advancing both medical science and patient care.
  • This partnership aims to explore the diverse applications of high-resolution cortical surface arrays in clinical settings, ranging from intraoperative monitoring to neurocritical care.

CodaMetrix Announces $40M Series B Financing to Advance Medical Coding Quality and Clinically Enrich Claims Data Through AI

Retrieved on: 
Tuesday, March 12, 2024
General Health, Health, Data Management, Technology, Artificial Intelligence, Organization, Mass General Brigham, Entrepreneurship, Partner (business rank), Acceleration, Artificial intelligence, GI, Radiology, University, Pathology, Mount Sinai Health System, Mass, Emerge Commerce, Medical device

Transformation Capital led the financing with continued support from existing investors SignalFire, Series A lead, and Frist Cressey Ventures.

Key Points: 
  • Transformation Capital led the financing with continued support from existing investors SignalFire, Series A lead, and Frist Cressey Ventures.
  • Series B financing will be used to further advance CodaMetrix’s AI-powered solutions which improve medical coding quality, produce clinically comprehensive data sets, reduce the overall cost of care, and alleviate administrative burden on providers.
  • “Medical coding is one of the most time-consuming, understaffed and inherently error-prone parts of the health system revenue cycle.
  • “Our game changing AI platform delivers vital automation which not only addresses these pain points but, more significantly, changes claims data from notoriously unreliable to clinically valuable.

Tom Oxley to Keynote 2024 Bioelectronic Medicine Forum in New York City

Retrieved on: 
Tuesday, March 19, 2024
General partnership, Patient, Beckman Coulter, Skin, MCRA, Litre, Mount Sinai Health System, Movement

NEW YORK, March 19, 2024 /PRNewswire/ -- Neurotech Reports , the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Seventh Annual Bioelectronic Medicine Forum will take place on April 5, 2024.

Key Points: 
  • NEW YORK, March 19, 2024 /PRNewswire/ -- Neurotech Reports , the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Seventh Annual Bioelectronic Medicine Forum will take place on April 5, 2024.
  • The keynote speaker at this year's event is Tom Oxley, CEO of Synchron and an interventional neurologist at Mount Sinai Health System.
  • For more information on the 2024 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: http://neurotechreports.com/pages/bioelectronic-medicine-forum.html .
  • Photo caption: Tom Oxley, Ph.D., M.D., will keynote the 2024 Bioelectronic Medicine Forum on April 5, 2024 in New York City.

New consortium of healthcare leaders announces formation of Trustworthy & Responsible AI Network (TRAIN), making safe and fair AI accessible to every healthcare organization

Retrieved on: 
Monday, March 11, 2024
Informatics, Algorithm, Responsibility, Information technology, Health, Biomedical Research, Patient, Cleveland Clinic, Approximation error, Artificial intelligence in healthcare, Microsoft, Public, AdventHealth, Mass General Brigham, Coalition, Science, Policy, Safety, Boston Children's Hospital, VUMC, Organization, Bias, Trust (social science), Research, AI, University, Nouvelle AI, MPH, Vanderbilt University Medical Center, Hospital, Sharp HealthCare, Internal medicine, Health informatics, Conference, Public health, Cardiology, Caregiver, MedStar Health, CHAI, HIMSS, Mount Sinai Health System, Medical device

New AI capabilities have the potential to transform the healthcare industry by enabling better care outcomes, improving efficiency and productivity, and reducing costs.

Key Points: 
  • New AI capabilities have the potential to transform the healthcare industry by enabling better care outcomes, improving efficiency and productivity, and reducing costs.
  • Enabling registration of AI used for clinical care or clinical operations through a secure online portal.
  • "By working together, TRAIN members aim to establish best practices for operationalizing responsible AI, helping improve patient outcomes and safety while fostering trust in healthcare AI."
  • "We are excited to join our TRAIN partners in the journey to accelerate AI innovation in an ethical, responsible and safe way."

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Retrieved on: 
Saturday, March 9, 2024
The Department, SAN, Immunodeficiency, Psoriasis, Doctor of Philosophy, Waldman, STAT1, IL22, MD, Mount Sinai Health System, Dermatitis, Atopic dermatitis, Biopsy, RNA-Seq, OASL, Rosacea, Laboratory, AAD, CXCL9, FA2H, Hospital, RNA, Immunology, IGA, Patient, Gene, PI3, Seborrhoeic dermatitis, Skin condition, Observational study, Skin, Research, Gene expression, American Academy, Vaccine

“We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.

Key Points: 
  • “We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.
  • These findings will help establish the groundwork for greater understanding of this very common condition.”
    “The pathophysiology of seborrheic dermatitis has been poorly understood.
  • In addition, the skin barrier disruption observed in seborrheic dermatitis has unique molecular underpinnings, primarily in the tight junction of the epithelial skin cells and lipid metabolism pathways.
  • These data demonstrate that seborrheic dermatitis is an immune disease with a uniquely polarized profile distinct from atopic dermatitis and plaque psoriasis.

Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

Retrieved on: 
Thursday, March 7, 2024
Diuretic, Ultrafiltration, Hospital, Section, Artificial intelligence, Randomized controlled trial, Mount Sinai Health System, Quality of life, Acute decompensated heart failure, Hierarchy, Aquapheresis, Valvular heart disease, Risk, Heart failure, Arrhythmia, AUF, ALD, History, Yale School of Medicine, Patient, HF, Machine learning, Cerebrovascular disease, THT, Mortality, Roflumilast, Pharmaceutical industry

MINNEAPOLIS, March 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced results from two new clinical data analyses from the AVOID-HF trial, which demonstrate the benefits of its Aquadex System in reducing heart failure readmissions at 30 days. Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.

Key Points: 
  • Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.
  • Key findings demonstrating the benefits of AUF include:
    Fewer heart failure events and heart failure hospitalizations: AUF patients had significantly fewer heart failure events within 30 days compared to ALD (90% vs 77.3% p=0.0138) and fewer heart failure hospitalizations for the AUF patients compared to the ALD patients (90.0% vs. 79.2% p=0.0321) within 30 days.
  • Key findings from the analysis include:
    Top predictors for 90-day heart failure events: Using ML, the study identified the top 10 predictors for 90-day heart failure events.
  • Strong results for super-responders: 90% of patients categorized as super-responders to AUF therapy within this model did not experience any 90-day heart failure events.

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Retrieved on: 
Thursday, February 8, 2024
IBD, Trial of the century, Division, Inflammatory bowel disease, Therapy, CAB, Nutrition, DRS, Mount Sinai Health System, Ulcerative colitis, Associate, Pharmaceutical industry

Drs.

Key Points: 
  • Drs.
  • Sands and Rieder will be advising Palisade on the advancement of its product candidates from preclinical studies to clinical trials.
  • “We are committed to advancing the treatment landscape for Inflammatory Bowel Disease (IBD) and believe that the appointment of these preeminent key opinion leaders will assist in the development of a precision approach for IBD treatment,” commented J.D.
  • Finley, Chief Executive Officer of Palisade.

The New York Academy of Medicine Launches Initiative to Build Health Systems Resilience

Retrieved on: 
Wednesday, February 7, 2024
ACT, Commissioner, Mental Hygiene, New York (state), COVID-19, Public, Commonwealth Fund, City, City & State, Commonwealth, Harvard Business School, Climate change, NYAM, Chair, Netflix, Environmental justice, Environmental protection, Joint Commission, Risk, Mount Sinai Health System, Disaster, Health, Northwell Health, Management

New York, NY, Feb. 07, 2024 (GLOBE NEWSWIRE) -- The New York Academy of Medicine (NYAM), an innovator in public health for more than 176 years, launches its first initiative in a multiyear plan to help build more resilient health systems in the era of climate change.

Key Points: 
  • New York, NY, Feb. 07, 2024 (GLOBE NEWSWIRE) -- The New York Academy of Medicine (NYAM), an innovator in public health for more than 176 years, launches its first initiative in a multiyear plan to help build more resilient health systems in the era of climate change.
  • NYAM’s Designing Health Systems Resilience program will begin to establish a community of practice among health executives, public health officials, payers, and policy-makers as a first step toward building a “Roadmap to Resilience,” providing recommendations for programming and partnerships to support healthcare and public health system resilience across New York.
  • Designing Health Systems Resilience is made possible by the generosity of our sponsors, including the Commonwealth Fund, Mount Sinai Health System, Netflix, and Northwell Health, and our media partner City & State New York.
  • Future phases of NYAM’s work with public health and health systems will explore support of resilience strategies and assessment for impact, sustainability, and potential for broader replication.

Clinique Partners with Icahn School of Medicine at Mount Sinai to Establish the Mount Sinai-Clinique Healthy Skin Dermatology Center

Retrieved on: 
Friday, February 2, 2024
Other Health, Research, General Health, Pharmaceutical, Philanthropy, Hospitals, Cosmetics, Retail, Science, Other Philanthropy, Other Science, Health, MD, Hospital, Exercise, Atopic dermatitis, Informatics, Allergy, Clinique, Partnership, Ophthalmology, Knowledge, Alopecia areata, Diet, Artificial intelligence, Health system, Nursing, Mount Sinai Hospital, Patient, Laboratory, State, Community, Skin condition, Skin, Disease, Doctor of Philosophy, Mount, Therapy, Ageing, School, Physician, News, Mount Sinai Health System, Geriatrics

Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center.

Key Points: 
  • Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center.
  • Research conducted under the Mount Sinai-Clinique Healthy Skin Dermatology Center aims to uncover scientific findings to accelerate the creation of new topical and systemic treatments that help alleviate allergic skin conditions.
  • The priority is to bridge basic science with practical application in the clinic to improve people’s lives through healthy skin.
  • Dr. David Orentreich is Assistant Clinical Professor of Dermatology at Icahn Mount Sinai, and he and Dr. Catherine Orentreich are members of the Mount Sinai Dermatology Advisory Board.